IDERA PHARMACEUTICALS INC's ticker is IDRA and the CUSIP is 45168K405. A total of 35 filers reported holding IDERA PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $11 | -99.9% | 31,700 | +1.3% | 0.00% | – |
| Q3 2022 | $12,000 | -14.3% | 31,300 | -0.6% | 0.00% | – |
| Q2 2022 | $14,000 | -95.0% | 31,500 | -88.4% | 0.00% | – |
| Q3 2021 | $280,000 | +71.8% | 271,640 | +117.1% | 0.00% | – |
| Q1 2021 | $163,000 | -95.6% | 125,094 | -87.7% | 0.00% | -100.0% |
| Q4 2020 | $3,718,000 | +81.0% | 1,013,149 | +5.6% | 0.00% | +100.0% |
| Q3 2020 | $2,054,000 | +11.2% | 959,630 | -7.0% | 0.00% | 0.0% |
| Q2 2020 | $1,847,000 | +128.6% | 1,031,947 | +68.6% | 0.00% | +100.0% |
| Q1 2020 | $808,000 | -18.5% | 612,149 | +12.3% | 0.00% | 0.0% |
| Q4 2019 | $992,000 | +1.5% | 545,037 | +61.2% | 0.00% | 0.0% |
| Q3 2019 | $977,000 | +24.1% | 338,025 | +14.7% | 0.00% | 0.0% |
| Q2 2019 | $787,000 | +21.8% | 294,625 | +16.4% | 0.00% | 0.0% |
| Q1 2019 | $646,000 | +296.3% | 253,150 | +330.8% | 0.00% | – |
| Q4 2018 | $163,000 | +23.5% | 58,762 | +296.1% | 0.00% | – |
| Q3 2018 | $132,000 | – | 14,837 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ABG Innovation Capital Partners III GP Ltd | 56,250 | $206,000 | 0.12% |
| Baker Brothers Advisors | 4,608,786 | $16,914,000 | 0.06% |
| Artal Group S.A. | 500,000 | $1,835,000 | 0.04% |
| HOLLENCREST CAPITAL MANAGEMENT | 90,000 | $331,000 | 0.04% |
| Spotlight Asset Group, Inc. | 21,500 | $79,000 | 0.03% |
| DCF Advisers, LLC | 18,755 | $69,000 | 0.03% |
| 683 Capital Management, LLC | 88,470 | $325,000 | 0.02% |
| Palo Alto Investors LP | 77,044 | $283,000 | 0.02% |
| Alpine Global Management, LLC | 13,966 | $51,000 | 0.01% |
| TCI Wealth Advisors, Inc. | 4,000 | $15,000 | 0.01% |